Causes and consequences of disrupted bone marrow function following autologous stem cell transplantation, a pilot study
Completed
- Conditions
- lymphomamyeloma10035227
- Registration Number
- NL-OMON42488
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
-Patients diagnosed with lymphoma or myeloma that have been treated with ASCT.
-At least 1 year following ASCT
-Age >18 years
Exclusion Criteria
-Age <18 years
-Signs of active disease related to lymphoma or myeloma
-Pregnancy
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To obtain information regarding the increased vulnerability of HSPC for<br /><br>chemotherapy, in vitro culture assays will be performed in the absence and<br /><br>presence of cytostatic agents, in the presence and absence of mesenchymal cells<br /><br>(MSC*s). The response of these cells will further be analyzed regarding the<br /><br>induction of stress response (p53) and DNA damage response by performing gene<br /><br>profiling and western blotting. In addition, the genetic and epigenetic<br /><br>background of these cells will be analyzed and correlated with the obtained<br /><br>results by performing targeted sequencing and Chip-seq. For these assays at<br /><br>least 105 cells are required per experiment.</p><br>
- Secondary Outcome Measures
Name Time Method <p>not applicable</p><br>